資本市場雷達

Novartis’s heart medicine Entresto recorded a 50% year-on-year sales decline in US dollars in the second quarter of 2026. In September, pelacarsen and del-desiran, previously listed for expected submissions over the next two years, both reported missed Phase 3 primary endpoints. Revenue erosion is already in the financial statements, while the filing assumptions for those two candidates need reassessment.

On August 24, 2026, GSK announced that Hibsago (bepirovirsen) had been approved in Japan for eligible adults with chronic hepatitis B. The Phase III results supporting the approval had already been published in May; this development moves a finite course of treatment from trial evidence into a treatment option for a defined population.

Pelacarsen’s Phase III Lp(a)HORIZON trial enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a). The September 4 initial announcements showed Lp(a) lowering but a missed primary cardiovascular endpoint. This should not be read as an effect precisely equal to zero, nor as a failure of the entire Lp(a) field. The September 4 announcements did not provide full effect estimates, event components, prespecified-population results or complete safety details.

PharmaEssentia’s story has entered the post-approval phase. The key questions are now physician adoption, payer access, long-term treatment persistence, supply capacity and fixed-cost execution. The Puerto Rico plan shows preparation for U.S. and global demand, but it remains a planned investment rather than an operating supply site. Clinical progress, competition and manufacturing commitments should be read on separate timelines.

諾華（Novartis）的心臟藥Entresto在2026年第二季美元銷售年減50%；進入9月，原列在未來兩年申請規劃中的pelacarsen與del-desiran，又先後公布第三期主要終點未達。收入侵蝕已反映在財報，兩項候選藥的申請前提卻需要重估。

The2026 Nobel Medicine Prize recognizes light-gated ion channels and optogenetics. From algae to causal neural experiments and visual-restoration research, scientific tools and product delivery demand different evidence, capital and responsibilities.

Two meta-analyses quantify hair-loss and gallbladder/biliary risk around GLP-1-related obesity treatment. Relative risk, absolute risk and different analytical pools must be kept separate, while dose, duration and weight-loss indication do not by themselves prove a speed-of-weight-loss mechanism. The article then examines how tolerability and persistence may shape product differentiation.

兩份統合分析把GLP-1相關減重藥的掉髮與膽囊／膽道風險量化：RR要和絕對風險分開看，減重用途、高劑量與較長療程的關聯也不能直接等同於減重速度因果。本文進一步討論耐受性、依從性與長期使用如何成為產品差異化。

Why pursue non-incretin programs alongside an established GLP-1 franchise? K-554’s neural-circuit hypothesis, human evidence and usable dose range frame the relationship between efficacy, tolerability, persistence and product value.

諾和諾德已有GLP-1減重產品，為何仍布局非腸泌素計畫？從K-554的神經迴路假說、人體證據進度與可用劑量，分析效果、耐受性及持續使用如何影響產品價值。

A U.S. household transaction study found that grocery spending fell 5.3% on average six months after GLP-1 adoption and 8.2% among higher-income households. Some luxury hotels are already testing smaller portions, protein-forward menus, zero-proof drinks and wellness services. The strategic question is whether hospitality operators can translate lower food volume into better service, pricing and repeat demand.

美國家戶交易研究顯示，採用 GLP-1 六個月後，雜貨支出平均下降 5.3%，高收入家庭下降 8.2%；部分高端飯店也開始測試小份餐、高蛋白、無酒精飲品與健康陪伴服務。真正的商業題目，不是客人吃少了多少，而是飯店能否把食物的量重新翻譯成服務、價格與回購。

Adding an ADC increased response rates but missed the prespecified PFS threshold and increased toxicity in EVOKE-03. What evidence would justify further development, and what must regional hypotheses and distinct TROP2 products demonstrate?

Ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the Phase 3 HARMONi-GI1 interim analysis, but the hazard ratio, median survival, curves, safety and subgroup results remain undisclosed.

FDA approval does not erase business risk. Iterum, Karyopharm and Theravance show how revenue, cost, pipeline and capital clocks can begin running at the same time after a drug reaches the market.

Historical Genmab milestones, Formosa's equity settlement and gross-profit-based collaboration, and PharmaEngine's first-half 2026 accounts show how contractual achievements become—or differ from—collectable proceeds.

藥證、付款事件與實際收款之間，有哪些條件？以Genmab歷史里程碑、台新藥的股票結算與毛利合作，以及智擎2026上半年財報，解析新藥授權生意如何從進展走向可運用資源。

Lilly's in vivo CAR-T acquisition and Novartis' subcutaneous formulation options address different delivery problems. Human evidence, drug exposure and payment terms clarify how each platform could create product value.

禮來押注體內CAR-T製程，諾華取得皮下劑型選擇權。從人體研究、藥物暴露到付款條件，解析兩種遞送平台如何形成產品價值。

大型併購共同溢價降溫不代表買方沒錢；當臨床證據、上市時點、權利結構與團隊承接能力都能驗證，少數資產的個別價值反而可能上升。

Novo Nordisk's collaboration with Anthropic tests scientific reasoning and R&D software engineering alongside capabilities provided by Valo, OpenAI and AWS. This analysis examines workflows, computational acceleration and collaboration economics, while distinguishing Taiwanese platform capabilities from proven partnerships and the experimental and clinical gates that remain.

諾和諾德與Anthropic合作測試科學推理及研發軟體工程，與Valo、OpenAI、AWS分別提供的能力形成對照。從研發流程、運算加速和合作款項拆解AI製藥的商業價值，並區分台灣平台能力、合作證據與仍須通過的實驗及臨床關卡。

Google Co-Scientist 從假說生成走向實驗執行，但真正的採購與產業價值仍取決於設備整合、可重現性、失敗紀錄與責任治理。

文獻在資料庫、定序檔在伺服器、蛋白質結構在另一套工具、分析程式留在某位研究員的電腦，最後的實驗紀錄又散落在不同表單。科學家花掉大量時間，不是在解生物學，而是在搬資料、補上下文、確認上一個人到底做了什麼。

一則「FDA 將增設 AI 副局長」的消息，這幾天讓 AI 製藥圈非常興奮。

Anthropic's Model Hardware Standard research preview gives AI agents a shared interface for microscopes, liquid handlers, robots and laser-control systems. The proof-of-concept results are important, but they do not mean autonomous laboratories are already mature.

做中樞神經藥物的人，手上可能握著一把很好的劍：抗體能抓到致病蛋白、基因療法能關掉錯誤基因、核酸藥物能精準沉默訊號。